50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
CEO of biggest PE firm predicts “social unrest” (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
Gold is about to SOAR – here’s what you need to do (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
CEO of biggest PE firm predicts “social unrest” (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
Gold is about to SOAR – here’s what you need to do (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
CEO of biggest PE firm predicts “social unrest” (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
Gold is about to SOAR – here’s what you need to do (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
CEO of biggest PE firm predicts “social unrest” (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
Gold is about to SOAR – here’s what you need to do (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage

Cyclacel Pharmaceuticals - CYCC Stock Forecast, Price & News

$1.26
+0.02 (+1.61%)
(As of 09/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.23
$1.32
50-Day Range
$1.10
$2.01
52-Week Range
$1.01
$6.10
Volume
51,391 shs
Average Volume
492,791 shs
Market Capitalization
$15.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

Cyclacel Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,249.2% Upside
$17.00 Price Target
Short Interest
Healthy
3.23% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.87mentions of Cyclacel Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.95) to ($2.85) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

535th out of 1,071 stocks

Pharmaceutical Preparations Industry

250th out of 531 stocks

CYCC stock logo

About Cyclacel Pharmaceuticals (NASDAQ:CYCC) Stock

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

Receive CYCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CYCC Stock News Headlines

Cyclacel Pharmaceuticals's Earnings Outlook
Cyclacel Pharmaceuticals Q4 2021 Earnings Preview
Cyclacel Pharmaceuticals, Inc. (CYCC)
See More Headlines
Receive CYCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CYCC Company Calendar

Last Earnings
8/10/2022
Today
9/28/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYCC
Employees
2,018
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+1,249.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-18,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.73 per share

Miscellaneous

Free Float
12,012,000
Market Cap
$15.80 million
Optionable
Not Optionable
Beta
1.19

Key Executives

  • Mr. Spiro George RombotisMr. Spiro George Rombotis (Age 63)
    Pres, CEO & Exec. Director
    Comp: $839.53k
  • Mr. Paul McBarron (Age 61)
    Exec. VP of Fin., CFO, COO, Sec. & Exec. Director
    Comp: $444.86k
  • Dr. Mark H. Kirschbaum M.D. (Age 61)
    Sr. VP & Chief Medical Officer
    Comp: $531.58k
  • Ms. Gill Christie (Age 65)
    Director of HR
  • Dr. Robert Westwood Ph.D. (Age 78)
    Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel.













CYCC Stock - Frequently Asked Questions

Should I buy or sell Cyclacel Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CYCC shares.
View CYCC analyst ratings
or view top-rated stocks.

What is Cyclacel Pharmaceuticals' stock price forecast for 2022?

2 equities research analysts have issued 12 month target prices for Cyclacel Pharmaceuticals' stock. Their CYCC share price forecasts range from $17.00 to $17.00. On average, they anticipate the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 1,249.2% from the stock's current price.
View analysts price targets for CYCC
or view top-rated stocks among Wall Street analysts.

How have CYCC shares performed in 2022?

Cyclacel Pharmaceuticals' stock was trading at $3.89 at the beginning of 2022. Since then, CYCC shares have decreased by 67.6% and is now trading at $1.26.
View the best growth stocks for 2022 here
.

When is Cyclacel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our CYCC earnings forecast
.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) announced its quarterly earnings results on Wednesday, August, 10th. The biotechnology company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.67) by $0.21. During the same quarter in the previous year, the business earned ($0.56) earnings per share.

When did Cyclacel Pharmaceuticals' stock split?

Cyclacel Pharmaceuticals shares reverse split before market open on Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 14th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO?

1 employees have rated Cyclacel Pharmaceuticals Chief Executive Officer Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among the company's employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA).

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

Who are Cyclacel Pharmaceuticals' major shareholders?

Cyclacel Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Sio Capital Management LLC (4.55%), Millennium Management LLC (1.04%), Renaissance Technologies LLC (0.63%) and Virtu Financial LLC (0.31%). Insiders that own company stock include Sam L Barker and Spiro George Rombotis.
View institutional ownership trends
.

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyclacel Pharmaceuticals' stock price today?

One share of CYCC stock can currently be purchased for approximately $1.26.

How much money does Cyclacel Pharmaceuticals make?

Cyclacel Pharmaceuticals (NASDAQ:CYCC) has a market capitalization of $15.80 million. The biotechnology company earns $-18,890,000.00 in net income (profit) each year or ($1.96) on an earnings per share basis.

How many employees does Cyclacel Pharmaceuticals have?

The company employs 2,018 workers across the globe.

How can I contact Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The official website for the company is www.cyclacel.com. The biotechnology company can be reached via phone at (908) 517-7330, via email at ir@cyclacel.com, or via fax at 866-271-3466.

This page (NASDAQ:CYCC) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.